



February 11, 2021

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject : Disclosure of the Outcome of the Meeting of the Board of Directors of HealthCare Global Enterprises Limited (“the Company”) held on February 11, 2021**

**Stock Code : BSE – 539787, NSE – HCG**

**Reference : Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015**

We wish to inform you that the Board of Directors of the Company (“Board”), at their meeting held on this day, February 11, 2021, *inter alia*, has considered and approved the following agenda:

1. Unaudited Financial Results, both Standalone and Consolidated (Limited Review) of the Company for the quarter and nine months ended December 31, 2020;
2. Issue and allotment of 8,000 (Eight Thousand) equity shares of the Company of Rs. 10 each, upon exercise of Employee Stock Options in accordance with the Employee Stock Option Scheme, 2014 of the Company.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2020;
2. Limited Review Report of the Statutory Auditors on the Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2020;

## HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



The results are also being uploaded on the Company's website at [www.hcgel.com](http://www.hcgel.com). The Meeting of the Board concluded at 4.25 P.M. Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For **HealthCare Global Enterprises Limited**

A handwritten signature in blue ink, appearing to read 'Sunu Manuel', written over a light blue horizontal line.

**Sunu Manuel**  
**Company Secretary & Compliance Officer**

**Encl: a/a.**

# B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park,  
Pebble Beach, B Block, 3<sup>rd</sup> Floor,  
Off Intermediate Ring Road,  
Bangaluru-560 071 India

Telephone: + 91 80 4682 3000  
Fax: + 91 80 4682 3999

## Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results of HealthCare Global Enterprises Limited under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

To  
Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of HealthCare Global Enterprises Limited (‘the Company’) for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 (‘the Statement’).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**  
Chartered Accountants  
Firm's Registration No. 101248W/W-100022



**Amit Somani**  
Partner

Membership No.060154  
UDIN: 21060154AAAAAO7782

Place: Bengaluru  
Date: 11 February 2021

Registered Office:

**HealthCare Global Enterprises Limited**

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2020**

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended	Preceding quarter	Corresponding	Nine months ended	Nine months ended	Previous year
		31 December 2020	ended 30 September 2020	quarter ended 31 December 2019	31 December 2020	31 December 2019	ended 31 March 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income</b>						
	(a) Revenue from operations	10,331	14,306	17,254	42,996	51,669	60,033
	(b) Income from government grant	55	50	44	156	89	124
	(c) Other income	828	556	313	1,725	794	1,086
	<b>Total income</b>	<b>17,234</b>	<b>15,112</b>	<b>17,611</b>	<b>44,877</b>	<b>52,552</b>	<b>70,043</b>
2	<b>Expenses</b>						
	(a) Purchases of medical and non-medical items	3,508	3,285	3,575	9,502	10,527	14,275
	(b) Changes in inventories	106	(30)	18	128	392	382
	(c) Employee benefits expense	3,579	3,413	3,561	9,898	10,666	14,269
	(d) Finance costs	1,400	1,309	2,141	5,008	6,120	8,299
	(e) Depreciation and amortisation expense	2,163	2,185	2,074	6,533	5,682	7,941
	(f) Medical consultancy charges	3,236	2,828	3,389	8,206	10,055	13,377
	(g) Other expenses	3,750	3,345	3,607	10,166	10,707	14,957
	<b>Total expenses</b>	<b>17,742</b>	<b>16,335</b>	<b>18,365</b>	<b>49,441</b>	<b>54,149</b>	<b>73,500</b>
3	<b>Loss before exceptional item and tax (1-2)</b>	<b>(508)</b>	<b>(1,223)</b>	<b>(754)</b>	<b>(4,564)</b>	<b>(1,597)</b>	<b>(3,457)</b>
4	Exceptional item (refer note 5 and 6)	875	-	-	875	-	3,089
5	<b>Loss before tax (3-4)</b>	<b>(1,383)</b>	<b>(1,223)</b>	<b>(754)</b>	<b>(5,439)</b>	<b>(1,597)</b>	<b>(6,546)</b>
6	<b>Tax expense</b>						
	- Deferred tax	(82)	(565)	(327)	(1,607)	(622)	(1,216)
	<b>Total taxes credit</b>	<b>(82)</b>	<b>(565)</b>	<b>(327)</b>	<b>(1,607)</b>	<b>(622)</b>	<b>(1,216)</b>
7	<b>Loss for the period / year (5-6)</b>	<b>(1,301)</b>	<b>(658)</b>	<b>(427)</b>	<b>(3,832)</b>	<b>(975)</b>	<b>(5,330)</b>
8	<b>Other comprehensive income / (loss)</b>						
	(i) Items that will not be reclassified subsequently to profit or loss						
	- Remeasurements of the defined benefit plans	-	-	-	-	-	(88)
	- Income tax effect on (i) above	-	-	-	-	-	31
	(ii) Items that will be reclassified to profit or loss						
	- Effective portion of gain/ (loss) on hedging instruments in a cash flow hedge	143	158	(8)	373	76	80
	- Income tax effect on (ii) above	(50)	(55)	2	(130)	(27)	(28)
	<b>Other comprehensive income / (loss) for the period / year, net of tax</b>	<b>93</b>	<b>103</b>	<b>(6)</b>	<b>243</b>	<b>49</b>	<b>(5)</b>
9	<b>Total comprehensive loss for the period / year (7+8)</b>	<b>(1,208)</b>	<b>(555)</b>	<b>(433)</b>	<b>(3,589)</b>	<b>(926)</b>	<b>(5,335)</b>
10	Paid-up equity share capital (Face value of Rs. 10 each)	12,535	12,526	8,867	12,535	8,867	8,869
11	Reserves, i.e., 'Other equity'						52,582
12	<b>Loss per equity share (face value of Rs. 10 each)</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Annualised</b>
	(a) Basic	(1.04)	(0.57)	(0.48)	(3.49)	(1.10)	(6.02)
	(b) Diluted	(1.04)	(0.57)	(0.48)	(3.49)	(1.10)	(6.02)
	See accompanying notes to the Standalone Financial Results						



HealthCare Global Enterprises Limited

CIN : LI5200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India  
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2020

Notes:

- 1 The statement of unaudited standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter and nine months ended 31 December 2020, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 11 February 2021. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.  

The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditors is unqualified.
- 2 The COVID-19 pandemic has been rapidly spreading throughout the world, including India. Governments around the world have been taking significant measures to curb the spread of the virus including imposing mandatory lockdowns and restrictions in activities including travel. Consequently, the scale of operations has reduced significantly, inter-state and intra-state movement restrictions have impacted both the patient's footfall and the healthcare workers. As a result of the lockdown, the likely revenue from mid of March 2020 and onwards has been impacted. The pandemic is likely to impact the Company operationally including its new projects.  


The Company has incurred losses in the current period. Management believes that it has taken into account the possible impacts of known events arising from COVID-19 pandemic in the preparation of the financial results including but not limited to its assessment of Company's liquidity and going concern and various estimates in relation to the financial results captions upto the date of adoption of Statement by the Board of Directors. During the current period, the Company has received Rs. 51,284 lakhs on issue of Equity shares and Warrants and the Company has prepared the financial results on Going concern basis (refer note 3a). Given the nature and duration of COVID-19, its impact on the financial results may differ from that estimated as at the date of approval of these financial results.
- 3 a) Pursuant to Investment Agreement ("Agreement") executed amongst the Company, Dr. B. S. Ajaikumar ("Promoter") and Aceso Company Pte. Ltd., Singapore ("Investor") on 04 June 2020 and approval of the shareholders of the Company received on 12 June 2020, preferential allotment of 29,516,260 Equity shares of the face value of Rs. 10 each, at a premium of Rs. 120 each (aggregating to Rs. 130 per equity share) and 18,560,663 Warrants, with a right to apply for and allotted one equity share of the face value of Rs. 10 each at a premium of Rs. 120 each (aggregating to Rs. 130 per Warrant) were made to the Investor on 28 July 2020. The total consideration on issue of Equity shares and exercise of all Warrants aggregates to Rs. 62,500 lakhs.  

As required under the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "ICDR Regulations"), Investor has remitted an amount Rs. 51,284 lakhs towards allotment of 29,516,260 equity shares at Rs. 130 per share (Rs. 38,371 lakhs), 100% consideration for allotment and subsequent exercise of 7,057,195 warrants at Rs. 130 per warrant (Rs. 9,174 lakhs) that was converted into equity and 25% of the consideration for remaining 11,503,468 warrants at Rs. 130 per warrant (Rs. 3,739 lakhs). The remaining 75% of the consideration i.e. Rs. 11,216 lakhs shall be payable by the Investor on the exercise of the Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the warrants.

b) Pursuant to the preferential allotment of Equity shares and Warrants to the Investor on 28 July 2020, mentioned above in note 3(a), ICDR Regulations required "open offer" by the Investor to public shareholders of the Company. The Open Offer was also completed on 28 August 2020 wherein JM Financial Limited, Manager to the Open Offer, had announced an open offer for the acquisition of up to 32,613,192 fully paid-up equity shares of face value of Rs. 10 each ("Equity Shares") from the Public Shareholders of the Company, representing 26% of the Expanded Voting Share Capital, at a price of Rs. 130/- per Equity Share aggregating to total consideration of Rs. 42,397 lakhs payable in cash. An aggregate of 26,048,478 equity shares were tendered and accepted in the Open offer.
- 4 Pursuant to the shareholders approval received on 12 June 2020, preferential allotment of 2,000,000 Series B Warrants, with a right to apply for and be allotted 1 Equity Share of the face value of Rs. 10 each of the Company, at a premium of Rs. 120 for each series B Warrant (aggregating to Rs. 130 per warrant), were made to Promoter.  

As required under the provisions of the ICDR Regulations, Promoter has remitted an amount equivalent to 25% of the Consideration i.e. Rs. 650 lakhs on issue of series B Warrant and the remaining 75% of the consideration i.e. Rs. 1,950 lakhs shall be payable by him on the exercise of the Series B Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the Series B Warrants.
- 5 During the year ended 31 March 2020, the Company performed impairment assessment for all its investment in the subsidiaries and joint ventures and recorded the impairment charge with respect to HCG NCHRI Oncology LLP amounting to Rs. 2,022 lakhs, Divachand Imaging LLP amounting to Rs. 90 lakhs and Apex HCG Oncology Hospitals LLP amounting to Rs. 977 lakhs respectively. Given the continued losses incurred and primarily due to weaker forecasts due to COVID-19, the recoverable amount of these investments (considering the future cash flows) were estimated to be lower than their carrying value, resulting into an impairment charge during the year ended 31 March 2020. This impairment charge has been disclosed as an exceptional item in the Statement.
- 6 During the quarter ended 31 December 2020, due to changes in business environment and weaker project viability due to COVID-19, the Cochin project has been abandoned. The Management have assessed and estimated that the related assets may not be recoverable. Hence an amount of Rs. 875 lakhs has been "written off" and presented as an exceptional item in the Statement.
- 7 The Code on Social Security 2020 ('Code'), which received the Presidential Assent on 28 September 2020, subsumes nine regulations relating to social security, retirement, and employee benefits. The Ministry of Labour and Employment ('Ministry') has released draft rules for the Code on 13 November 2020 and has invited suggestions from stake holders. The suggestions received are under consideration by the Ministry. The effective date of the Code has not yet been notified and the related rules to ascertain the financial impact are yet to be finalized and notified. In view of this the impact of the changes on the financial result if any will be assessed and recognised post notification of the relevant rules.
- 8 Pursuant to the shareholders' agreement dated 22 March 2013 and Share Purchase agreement dated 27 November 2020 entered amongst the Company, BACC HealthCare Private Limited ("BACC") and the minority shareholders in BACC, the Company has acquired the remaining 49.9% share capital of BACC from the minority shareholders. The consideration amounting to Rs. 6,833 lakhs including interest of Rs. 206 lakhs has been settled during the quarter ending 31 December 2020.
- 9 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

Bengaluru, 11 February 2021

  
Dr. B. S. Ajaikumar  
Executive Chairman



# B S R & Co. LLP

Chartered Accountants

Telephone: + 91 80 4682 3000  
Fax: + 91 80 4682 3999

Embassy Golf Links Business Park,  
Pebble Beach, B Block, 3<sup>rd</sup> Floor,  
Off Intermediate Ring Road,  
Bangaluru-560 071 India

## **Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

To  
Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of HealthCare Global Enterprises Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net loss after tax and total comprehensive loss of its associate and a joint venture for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Listing Regulations.
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



Registered Office:

**BSR & Co. LLP****Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) (continued)**

4. The Statement includes the results of the following entities:

<b>Sl. No.</b>	<b>Name of the Entity</b>	<b>Subsidiary/ Associate/ Joint</b>	<b>Country of incorporation</b>
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
5	HCG NCHRI Oncology LLP	Subsidiary	India
6	HCG EKO Oncology LLP	Subsidiary	India
7	APEX HCG Oncology Hospitals LLP	Subsidiary	India
8	HCG Manavata Oncology LLP	Subsidiary	India
9	Niruja Product Development & Healthcare Research Private Limited	Subsidiary	India
10	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
11	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
12	HCG Sun Hospitals LLP	Subsidiary	India
13	HCG (Mauritius) Private Limited	Step-down subsidiary	Mauritius
14	HealthCare Global (Africa) Private Limited Group	Associate	Mauritius
15	Strand Life Sciences Private Limited	Joint Venture	India

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**B S R & Co. LLP**

**Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) (continued)**

6. We did not review the interim financial information / financial results of four (4) subsidiaries and one (1) step-down subsidiary included in the Statement, whose interim financial information / financial results reflect total revenues of Rs. 1,940 lakhs and Rs. 4,948 lakhs, total net loss after tax of Rs. 1,114 lakhs and Rs. 3,131 lakhs and total comprehensive loss of Rs. 1,140 lakhs and Rs. 3,210 lakhs, for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020, respectively, as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also includes the Group’s share of net profit of Rs. 24 lakhs and net loss of Rs. 124 lakhs and total comprehensive income of Rs. 34 lakhs and total comprehensive loss Rs. 227 lakhs for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020, respectively, as considered in the Statement, in respect of an associate and a joint venture, whose interim financial information/ financial results have not been reviewed by us. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, an associate and a joint venture, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Co. LLP**  
Chartered Accountants  
Firm's Registration No. 101248W/W-100022



**Amit Somani**  
Partner  
Membership No. 060154  
UDIN: 21060154AAAAAN5826

Place: Bengaluru  
Date: 11 February 2021



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India  
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2020

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended	Preceding quarter	Corresponding	Nine months ended	Nine months ended	Previous year
		31 December 2020	ended 30 September 2020	quarter ended 31 December 2019	31 December 2020	31 December 2019	ended 31 March 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income</b>						
	(a) Revenue from operations	27,294	24,686	27,697	71,215	82,284	109,234
	(b) Income from government grant	107	106	96	324	243	330
	(c) Other income	582	401	246	1,255	528	697
	<b>Total income</b>	<b>27,983</b>	<b>25,193</b>	<b>28,039</b>	<b>72,794</b>	<b>83,055</b>	<b>110,261</b>
2	<b>Expenses</b>						
	(a) Purchases of medical and non-medical items	6,294	5,950	6,070	16,459	17,538	23,635
	(b) Changes in inventories	135	(137)	15	253	374	351
	(c) Employee benefits expense	5,117	4,908	5,249	14,213	15,641	20,803
	(d) Finance costs	2,871	2,716	3,611	9,326	10,185	13,765
	(e) Depreciation and amortisation expense	4,183	3,960	3,770	12,084	10,639	14,845
	(f) Medical consultancy charges	6,143	5,558	6,172	15,756	18,559	24,507
	(g) Other expenses	5,928	5,511	5,714	16,135	16,799	23,049
	<b>Total expenses</b>	<b>30,671</b>	<b>28,466</b>	<b>30,601</b>	<b>84,226</b>	<b>89,735</b>	<b>120,955</b>
3	Loss before share of profit/(loss) of an associate / joint venture, exceptional items and tax (1-2)	(2,688)	(3,273)	(2,562)	(11,432)	(6,680)	(10,694)
4	Share of profit/(loss) of an associate / joint venture	24	44	(222)	(124)	(1,078)	(1,232)
5	Loss before exceptional items and tax (3+4)	(2,664)	(3,229)	(2,784)	(11,556)	(7,758)	(11,926)
6	Exceptional item (refer note 5)	875	-	-	875	-	-
7	Loss before tax (5-6)	(3,539)	(3,229)	(2,784)	(12,431)	(7,758)	(11,926)
8	Tax expense						
	- Current tax	68	53	60	131	160	246
	- Deferred tax	(134)	(582)	72	(1,828)	(417)	373
	<b>Total tax expense/ (credit)</b>	<b>(66)</b>	<b>(529)</b>	<b>132</b>	<b>(1,697)</b>	<b>(257)</b>	<b>619</b>
9	Loss for the period / year (7-8)	(3,473)	(2,700)	(2,916)	(10,734)	(7,501)	(12,545)
10	<b>Other comprehensive income</b>						
	(i) Items that will not be reclassified subsequently to profit or loss						
	- Remeasurements of the defined benefit plans	-	-	-	-	-	(111)
	- Income tax effect on (i) above	-	-	-	-	-	40
	(ii) Items that will be reclassified to profit or loss						
	- Exchange differences on translation of financial statements of foreign operations	(14)	(84)	131	(181)	36	67
	- Effective portion of gain/ (loss) on hedging instruments in a cash flow hedge	143	158	(8)	373	76	80
	- Income tax effect on (ii) above	(50)	(55)	2	(130)	(27)	(28)
	<b>Other comprehensive income for the period / year, net of taxes</b>	<b>79</b>	<b>19</b>	<b>125</b>	<b>62</b>	<b>85</b>	<b>48</b>
11	<b>Total comprehensive loss for the period / year (9+10)</b>	<b>(3,394)</b>	<b>(2,681)</b>	<b>(2,791)</b>	<b>(10,672)</b>	<b>(7,416)</b>	<b>(12,497)</b>
	<b>Loss for the period / year attributable to:</b>						
	Owners of the Company	(2,925)	(2,229)	(2,281)	(9,129)	(6,311)	(10,669)
	Non-controlling interests	(548)	(471)	(635)	(1,605)	(1,190)	(1,876)
	<b>Other comprehensive income / (loss) for the period / year attributable to</b>						
	Owners of the Company	79	19	125	62	85	51
	Non-controlling interests	-	-	-	-	-	(3)
	<b>Total comprehensive loss for the period / year attributable to</b>						
	Owners of the Company	(2,846)	(2,210)	(2,156)	(9,067)	(6,226)	(10,618)
	Non-controlling interests	(548)	(471)	(635)	(1,605)	(1,190)	(1,879)
12	Paid-up equity share capital (Face value of Rs. 10 each)	12,535	12,526	8,867	12,535	8,867	8,869
13	Reserves, i.e., 'Other equity'						29,256
14	<b>Loss per share (face value of Rs. 10 each)</b>	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic	(2.33)	(1.94)	(2.57)	(8.32)	(7.13)	(12.05)
	(b) Diluted	(2.33)	(1.94)	(2.57)	(8.32)	(7.13)	(12.05)
	See accompanying notes to the Consolidated Financial Results						



HealthCare Global Enterprises Limited

CIN : LI5200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India


Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2020

Notes:

- 1 The statement of unaudited consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture, for the quarter and nine months ended 31 December 2020, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 11 February 2021. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.  
  
The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditors is unqualified.
- 2 The COVID-19 pandemic has been rapidly spreading throughout the world, including India. Governments around the world have been taking significant measures to curb the spread of the virus including imposing mandatory lockdowns and restrictions in activities including travel. Consequently, the scale of operations has reduced significantly, inter-state and intra-state movement restrictions have impacted both the patient's footfall and the healthcare workers. As a result of the lockdown, the likely revenue from mid of March 2020 and onwards has been impacted. The pandemic is likely to impact the Group operationally including its new projects and IVF business.  
  
The Group has incurred losses in the current period. Management believes that it has taken into account the possible impacts of known events arising from COVID-19 pandemic in the preparation of the financial results including but not limited to its assessment of Group's liquidity and going concern and various estimates in relation to the financial results captions upto the date of adoption of Statement by the Board of Directors. During the current period, the Company has received Rs. 51,284 lakhs on issue of Equity shares and Warrants and the Company has prepared the financial results on Going concern basis (refer note 3a). Given the nature and duration of COVID-19, its impact on the financial results may differ from that estimated as at the date of approval of these financial results.
- 3 a) Pursuant to Investment Agreement ("Agreement") executed amongst the Company, Dr. B. S. Ajaikumar ("Promoter") and Aceso Company Pte. Ltd., Singapore ("Investor") on 04 June 2020 and approval of the shareholders of the Company received on 12 June 2020, preferential allotment of 29,516,260 Equity shares of the face value of Rs. 10 each, at a premium of Rs. 120 each (aggregating to Rs. 130 per equity share) and 18,560,663 Warrants, with a right to apply for and be allotted one equity share of the face value of Rs. 10 each at a premium of Rs. 120 each (aggregating to Rs. 130 per Warrant) were made to the Investor on 28 July 2020. The total consideration on issue of Equity shares and exercise of all Warrants aggregates to Rs. 62,500 lakhs.  
As required under the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "ICDR Regulations"), Investor has remitted an amount Rs. 51,284 lakhs towards allotment of 29,516,260 equity shares at Rs. 130 per share (Rs. 38,371 lakhs), 100% consideration for allotment and subsequent exercise of 7,057,195 warrants at Rs. 130 per warrant (Rs. 9,174 lakhs) and 25% of the consideration for remaining 11,503,468 warrants at Rs. 130 per warrant (Rs. 3,739 lakhs). The remaining 75% of the consideration i.e. Rs. 11,216 lakhs shall be payable by the Investor on the exercise of the Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the warrants.  
b) Pursuant to the preferential allotment of Equity shares and Warrants to the Investor on 28 July 2020, mentioned above in note 3(a), ICDR Regulations required "open offer" by the Investor to public shareholders of the Company. The Open Offer was also completed on 28 August 2020 wherein JM Financial Limited, Manager to the Open Offer, had announced an open offer for the acquisition of up to 32,613,192 fully paid-up equity shares of face value of Rs. 10 each ("Equity Shares") from the Public Shareholders of the Company, representing 26% of the Expanded Voting Share Capital, at a price of Rs. 130/- per Equity Share aggregating to total consideration of Rs. 42,397 lakhs payable in cash. An aggregate of 26,048,478 equity shares were tendered and accepted in the Open offer.
- 4 Pursuant to the shareholders approval received on 12 June 2020, preferential allotment of 2,000,000 Series B Warrants, with a right to apply for and be allotted 1 Equity Share of the face value of Rs. 10 each of the Company, at a premium of Rs. 120 for each series B Warrant (aggregating to Rs. 130 per warrant), were made to Promoter.  
As required under the provisions of the ICDR Regulations, Promoter has remitted an amount equivalent to 25% of the Consideration i.e. Rs. 650 lakhs on issue of series B Warrant and the remaining 75% of the consideration i.e. Rs. 1,950 lakhs shall be payable by him on the exercise of the Series B Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the Series B Warrants.
- 5 During the quarter ended 31 December 2020, due to changes in business environment and weaker project viability due to COVID-19, the Cochin project has been abandoned. The Management have assessed and estimated that the related assets may not be recoverable. Hence an amount of Rs. 875 lakhs has been "written off" and presented as an exceptional item in the Statement.
- 6 The Code on Social Security 2020 ('Code'), which received the Presidential Assent on 28 September 2020, subsumes nine regulations relating to social security, retirement, and employee benefits. The Ministry of Labour and Employment ('Ministry') has released draft rules for the Code on 13 November 2020 and has invited suggestions from stake holders. The suggestions received are under consideration by the Ministry. The effective date of the Code has not yet been notified and the related rules to ascertain the financial impact are yet to be finalized and notified. In view of this the impact of the changes on the financial result if any will be assessed and recognised post notification of the relevant rules.
- 7 Pursuant to the shareholders' agreement dated 22 March 2013 and Share Purchase agreement dated 27 November 2020 entered amongst the Company, BACC HealthCare Private Limited ("BACC") and the minority shareholders in BACC, the Company has acquired the remaining 49.9% share capital of BACC from the minority shareholders. The consideration amounting to Rs. 6,833 lakhs including interest of Rs. 206 lakhs has been settled during the quarter ending 31 December 2020.
- 8 The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

For and on behalf of the Board of Directors

  
Dr. B. S. Ajaikumar  
Executive Chairman

Bengaluru, 11 February 2021

